Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.
Samalin E, Afchain P, Thézenas S, Abbas F, Romano O, Guimbaud R, Bécouarn Y, Desseigne F, Edeline J, Mitry E, Bouché O, Adenis A, Aparicio T, Dorval E, Kramar A, Ychou M. Samalin E, et al. Clin Res Hepatol Gastroenterol. 2011 Jan;35(1):48-54. doi: 10.1016/j.gcb.2010.06.010. Clin Res Hepatol Gastroenterol. 2011. PMID: 21634054
Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study.
Duffour J, Thézenas S, Dereure O, Garcin A, Caron J, Samalin E, Portales F, Fiess C, Chalbos P, Gestin-Boyer C, Ychou M, Guillot B. Duffour J, et al. Among authors: samalin e. Eur J Cancer. 2010 Dec;46(18):3169-74. doi: 10.1016/j.ejca.2010.03.008. Epub 2010 Apr 21. Eur J Cancer. 2010. PMID: 20417092
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.
Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, Kramar A, Samalin E, Portales F, Bibeau F, Crapez-Lopez E, Bleuse JP, Ychou M. Assenat E, et al. Among authors: samalin e. Oncologist. 2011;16(11):1557-64. doi: 10.1634/theoncologist.2011-0141. Epub 2011 Oct 20. Oncologist. 2011. PMID: 22016477 Free PMC article. Clinical Trial.
Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Mazard T, Ychou M, Thezenas S, Poujol S, Pinguet F, Thirion A, Bleuse JP, Portales F, Samalin E, Assenat E. Mazard T, et al. Among authors: samalin e. Cancer Chemother Pharmacol. 2012 Mar;69(3):807-14. doi: 10.1007/s00280-011-1764-z. Epub 2011 Oct 30. Cancer Chemother Pharmacol. 2012. PMID: 22037922 Clinical Trial.
71 results